WO1997028104A3 - Puffersysteme zur stabilisierung pharmazeutischer zubereitungen - Google Patents

Puffersysteme zur stabilisierung pharmazeutischer zubereitungen Download PDF

Info

Publication number
WO1997028104A3
WO1997028104A3 PCT/DE1996/002488 DE9602488W WO9728104A3 WO 1997028104 A3 WO1997028104 A3 WO 1997028104A3 DE 9602488 W DE9602488 W DE 9602488W WO 9728104 A3 WO9728104 A3 WO 9728104A3
Authority
WO
WIPO (PCT)
Prior art keywords
buffer systems
pharmaceutical preparations
stabilizing pharmaceutical
stabilizing
buffer
Prior art date
Application number
PCT/DE1996/002488
Other languages
English (en)
French (fr)
Other versions
WO1997028104A8 (de
WO1997028104A2 (de
Inventor
Andreas Sachse
Ralf-Siegbert Hauck
Georg Roessling
Detlef Goeritz
Original Assignee
Schering Ag
Andreas Sachse
Ralf-Siegbert Hauck
Georg Roessling
Detlef Goeritz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag, Andreas Sachse, Ralf-Siegbert Hauck, Georg Roessling, Detlef Goeritz filed Critical Schering Ag
Priority to AU18704/97A priority Critical patent/AU1870497A/en
Priority to EP96946112A priority patent/EP0877628A2/de
Priority to JP9527225A priority patent/JP2000504334A/ja
Publication of WO1997028104A2 publication Critical patent/WO1997028104A2/de
Publication of WO1997028104A3 publication Critical patent/WO1997028104A3/de
Publication of WO1997028104A8 publication Critical patent/WO1997028104A8/de
Priority to NO983464A priority patent/NO983464D0/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265Citric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06Aminosugars

Abstract

Die Anmeldung betrifft neue Puffersysteme, bestehend aus einem physiologisch verträglichen Amin und einer Carbonsäure, für die Herstellung pharmazeutischer Mittel.
PCT/DE1996/002488 1996-01-29 1996-12-20 Puffersysteme zur stabilisierung pharmazeutischer zubereitungen WO1997028104A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU18704/97A AU1870497A (en) 1996-01-29 1996-12-20 Buffer systems for use in stabilizing pharmaceutical preparations
EP96946112A EP0877628A2 (de) 1996-01-29 1996-12-20 Puffersysteme zur stabilisierung pharmazeutischer zubereitungen
JP9527225A JP2000504334A (ja) 1996-01-29 1996-12-20 医薬製剤を安定化するための緩衝系
NO983464A NO983464D0 (no) 1996-01-29 1998-07-28 Buffersystemer for stabilisering av farmas°ytiske preparater

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19604230 1996-01-29
DE19604230.5 1996-01-29

Publications (3)

Publication Number Publication Date
WO1997028104A2 WO1997028104A2 (de) 1997-08-07
WO1997028104A3 true WO1997028104A3 (de) 1997-09-12
WO1997028104A8 WO1997028104A8 (de) 1997-12-18

Family

ID=7784639

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1996/002488 WO1997028104A2 (de) 1996-01-29 1996-12-20 Puffersysteme zur stabilisierung pharmazeutischer zubereitungen

Country Status (7)

Country Link
EP (1) EP0877628A2 (de)
JP (1) JP2000504334A (de)
AU (1) AU1870497A (de)
CA (1) CA2244213A1 (de)
DE (1) DE19648650C2 (de)
NO (1) NO983464D0 (de)
WO (1) WO1997028104A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250153B2 (en) * 2002-12-12 2007-07-31 Biophysica Research, Inc. Contrast media formulations having improved biological tolerance
JP2005170928A (ja) * 2003-10-21 2005-06-30 Konica Minolta Medical & Graphic Inc リポソーム含有x線造影剤およびその製造方法
JP2005170923A (ja) * 2003-10-21 2005-06-30 Konica Minolta Medical & Graphic Inc リポソーム含有x線造影剤およびその製造方法
JP2005220034A (ja) * 2004-02-03 2005-08-18 Konica Minolta Medical & Graphic Inc X線検査用造影剤の製造方法
JP4654590B2 (ja) * 2004-03-31 2011-03-23 コニカミノルタエムジー株式会社 X線ct用造影組成物およびその製造方法
WO2006009022A1 (ja) * 2004-07-21 2006-01-26 Konica Minolta Medical & Graphic, Inc. リポソーム含有x線造影剤およびその製造方法
CA2793277C (en) 2010-03-23 2018-09-04 Ge Healthcare As Preparation of stabilised x-ray diagnostic composition
ES2733061T3 (es) 2012-08-10 2019-11-27 Taiho Pharmaceutical Co Ltd Dispersión acuosa de liposomas encapsulantes de oxaliplatino estable y método para estabilización de la misma
CA2927968C (en) 2013-10-25 2023-02-21 Psioxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
JP6867639B2 (ja) * 2016-10-11 2021-05-12 学校法人 聖マリアンナ医科大学 非イオン性ヨード造影剤の結合体
GB201801614D0 (en) * 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
EP4011369A1 (de) 2020-12-14 2022-06-15 G.L. Pharma GmbH Wässrige pharmazeutische zusammensetzung mit tapentadoltartrat
JP7372429B1 (ja) 2022-10-31 2023-10-31 キユーピー株式会社 エマルジョン、及びその製造方法
JP7353453B1 (ja) 2022-10-31 2023-09-29 キユーピー株式会社 エマルジョン、及びその製造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013636A1 (en) * 1990-03-09 1991-09-19 Cockbain, Julian, Roderick, Michaelson Contrast media
DE4121568A1 (de) * 1991-04-22 1992-10-29 Schering Ag Verfahren und vorrichtung zur herstellung eines kontrastmediums aus einem konzentrat
WO1994014478A1 (en) * 1992-12-24 1994-07-07 Bracco S.P.A. Aqueous injectable formulations useful for radio-diagnosis comprising iodinated aromatic compounds used as x-ray contrast media

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4278654A (en) * 1978-07-04 1981-07-14 Nyegaard & Co. A/S Process for the preparation of a sterile injectable physiologically acceptable solution of an X-ray contrast agent and solutions of the X-ray contrast agent and a buffer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013636A1 (en) * 1990-03-09 1991-09-19 Cockbain, Julian, Roderick, Michaelson Contrast media
DE4121568A1 (de) * 1991-04-22 1992-10-29 Schering Ag Verfahren und vorrichtung zur herstellung eines kontrastmediums aus einem konzentrat
WO1994014478A1 (en) * 1992-12-24 1994-07-07 Bracco S.P.A. Aqueous injectable formulations useful for radio-diagnosis comprising iodinated aromatic compounds used as x-ray contrast media

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A. M. KAKAKIOS; ET AL: "Effect of Locally Administered Heparins on Delayed-Type Hipersensitivity Reactions", INT. ARCH. ALLERGY APPL. IMMUNOL., vol. 93, no. 4, 1990, BASEL (CH), pages 300 - 7, XP000677161 *

Also Published As

Publication number Publication date
WO1997028104A8 (de) 1997-12-18
NO983464L (no) 1998-07-28
NO983464D0 (no) 1998-07-28
WO1997028104A2 (de) 1997-08-07
CA2244213A1 (en) 1997-08-07
DE19648650A1 (de) 1997-08-07
EP0877628A2 (de) 1998-11-18
AU1870497A (en) 1997-08-22
JP2000504334A (ja) 2000-04-11
DE19648650C2 (de) 1998-07-02

Similar Documents

Publication Publication Date Title
ZA975943B (en) Aqueous formulations of peptides.
EP0645136A3 (de) Pharmazeutisches Präparat des Typs: physiologisch aktive Substanz mit verlängerter Freisetzung.
AU3992697A (en) Pharmaceutical preparations for intranasal administration
HK1047575A1 (en) Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containingthe same.
HK1018396A1 (en) Delivery system of an active agent.
HK1030768A1 (en) Cyclic amino acids and derivatives thereof useful as pharmaceutical agents.
HK1045646A1 (zh) 蛋白質穩定化的藥理學活性劑,其製備方法及其使用方法
AU1881795A (en) Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
AP9801392A0 (en) Concentrated antibody preparation.
HRP970694B1 (en) New aqueous medicament preparations for the produc
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
WO1997028104A8 (de) Puffersysteme zur stabilisierung pharmazeutischer zubereitungen
HUP0103793A3 (en) N-(2-aryl-propionyl)-sulfonamids, their use and pharmaceutical preparations containing them
NZ298677A (en) Hydroxamic acid derivatives, preparation and pharmaceutical compositions thereof
AU7214796A (en) Novel amino acid derivatives, their preparation and use
ZA200007415B (en) Amino acid derivatives and drugs containing the same as the active ingredient.
AU2294097A (en) Novel carboxylic acid derivatives, their preparation and use
AU5591296A (en) N-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl)benzamide derivatives, their preparation and their application in therapeutics
ZA9710243B (en) 3-Amidochromanylsulfonyl(thio)ureas, processes for their preparation, their use, and pharmaceutical preparations comprising them.
AU2636497A (en) Novel carboxylic acid derivatives, their preparation and use
AU3695297A (en) Alfa-amino acid amides, preparation thereof and the therapeutical use thereof
WO2004058186A3 (en) Formulations for pulmonary delivery
AP9901472A0 (en) Crystalline pharmaceutical product.
ZA200300777B (en) Process for the preparation of peptide salts, their use and pharmaceutical preparations comprising the peptide salts.
AU1251295A (en) Substituted benzimidazole, processes for its preparation and its pharmaceutical use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WS Later publication of a supplementary international search report
WWE Wipo information: entry into national phase

Ref document number: 1996946112

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2244213

Country of ref document: CA

Ref country code: CA

Ref document number: 2244213

Kind code of ref document: A

Format of ref document f/p: F

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1996946112

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996946112

Country of ref document: EP